幼年型粒单核细胞白血病:谁在掌控方向?
本文综述幼年型粒单核细胞白血病(JMML)的病理生物学与临床分型:约90%患者携带5个基因之一的分子改变,临床病程差异大,多数患儿需异基因造血干细胞移植,约15%可自发缓解,近期全基因组DNA甲基化谱可预测结局。
要点
- 约90%的JMML患者携带PTPN11、NRAS、KRAS、NF1或CBL基因之一的分子改变,定义遗传与临床不同的亚型。
- 疾病临床病程差异大,可部分由年龄、血红蛋白F水平和血小板计数预测。
- 多数患儿需异基因造血干细胞移植以获得长期无白血病生存,约15%患者最终自发缓解。
核心结论
- JMML是幼儿期独特的克隆性造血疾病,被世界卫生组织归类为骨髓增殖性/骨髓增生异常性重叠肿瘤,其病理生物学以Ras信号转导通路组成性激活为特征。
- 理解JMML的基因组与表观基因组基础不仅将极大改善精准决策,也将成为药物开发和未来合作试验的基础。
研究设计与样本
- 本文为综述,围绕JMML的病理生物学、遗传学亚型、临床病程与结局预测进行总结,未报告系统检索范围。
主要发现
- 约90%的JMML患者携带PTPN11、NRAS、KRAS、NF1或CBL 5个基因中1个的分子改变,这些改变定义遗传和临床上不同的亚型。
- PTPN11、NRAS和KRAS突变型JMML以非综合征儿童中的杂合性体细胞功能获得性突变为特征。
- 1型神经纤维瘤病中的JMML和CBL综合征儿童的JMML这2个亚型由种系Ras疾病及造血细胞中相应基因的获得性双等位基因失活所定义。
- 疾病临床病程差异很大,可部分由年龄、血红蛋白F水平和血小板计数预测。
- 最近,全基因组DNA甲基化谱鉴定出与临床和遗传特征相关、并对结局高度预测的独特甲基化特征。
关键数值与推荐
- 约90%的患者携带PTPN11、NRAS、KRAS、NF1或CBL 5个基因中1个的分子改变。
- 多数儿童需要异基因造血干细胞移植以获得长期无白血病生存。
- 约15%的患者疾病最终会自发缓解,因此前瞻性识别这些病例是临床必需。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of early childhood. It is classified as an overlap myeloproliferative/myelodysplastic neoplasm by the World Health Organization and shares some features with chronic myelomonocytic leukemia in adults. JMML pathobiology is characterized by constitutive activation of the Ras signal transduction pathway. About 90% of patients harbor molecular alterations in 1 of 5 genes (PTPN11, NRAS, KRAS, NF1, or CBL), which define genetically and clinically distinct subtypes. Three of these subtypes, PTPN11-, NRAS-, and KRAS-mutated JMML, are characterized by heterozygous somatic gain-of-function mutations in nonsyndromic children, whereas 2 subtypes, JMML in neurofibromatosis type 1 and JMML in children with CBL syndrome, are defined by germline Ras disease and acquired biallelic inactivation of the respective genes in hematopoietic cells. The clinical course of the disease varies widely and can in part be predicted by age, level of hemoglobin F, and platelet count. The majority of children require allogeneic hematopoietic stem cell transplantation for long-term leukemia-free survival, but the disease will eventually resolve spontaneously in ∼15% of patients, rendering the prospective identification of these cases a clinical necessity. Most recently, genome-wide DNA methylation profiles identified distinct methylation signatures correlating with clinical and genetic features and highly predictive for outcome. Understanding the genomic and epigenomic basis of JMML will not only greatly improve precise decision making but also be fundamental for drug development and future collaborative trials.
引用
- Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Blood. 2019. PMID: 30670449. doi:10.1182/blood-2018-11-844688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。